Here are five highlights:
1. The company saw revenues of $4.2 million for the first quarter 2017, compared to $8.4 million for the same period in the year prior.
2. Cytokinetics’ net loss was $25.9 million, compared to $12.5 million in 2016.
3. The company’s cash, cash equivalents and investments were $257.2 million as of March 31, 2017.
4. The company recorded total research and development costs of $19.3 million for the first quarter of 2017.
5. Cytokinetics advanced its muscle biology program, especially with its VITALITY-ALS study. The trial’s last patients moved through their primary efficacy endpoint visits in the first quarter of 2017.
More articles on devices:
Aurora Spine reports 2016 revenue of $6.76M — 5 highlights
RTI Surgical releases Q1 financial results — 5 insights
Exactech Q1 2017 revenue hits $69.5M — 8 highlights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
